PARP inhibitors: a treatment option for AML?

Lan Wang; Pierre-Jacques Hamard; Stephen D. Nimer

doi:https://doi.org/10.1038/nm.4007

doi.org/10.1038/nm.4007

PARP inhibitors: a treatment option for AML?

Lan Wang

22

,

Pierre-Jacques Hamard

12

,

Stephen D. Nimer

4

Nature Medicine82.90

Published: Dec 1, 2015

Abstract

A new study provides a rationale for the use of poly (ADP-ribose) polymerase (PARP) inhibitors to trigger irreparable DNA damage as a therapeutic approach in acute myeloid leukemia (AML). It also provides support for combining PARP inhibitors with agents that reduce HOXA9 protein...